261 related articles for article (PubMed ID: 33307091)
21. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
22. Tumour suppressors hamartin and tuberin: intracellular signalling.
Krymskaya VP
Cell Signal; 2003 Aug; 15(8):729-39. PubMed ID: 12781866
[TBL] [Abstract][Full Text] [Related]
23. Tuberous sclerosis complex: Recent advances in manifestations and therapy.
Wataya-Kaneda M; Uemura M; Fujita K; Hirata H; Osuga K; Kagitani-Shimono K; Nonomura N;
Int J Urol; 2017 Sep; 24(9):681-691. PubMed ID: 28667702
[TBL] [Abstract][Full Text] [Related]
24. [Tuberous Sclerosis Complex].
Kaneda M
Brain Nerve; 2019 Apr; 71(4):374-379. PubMed ID: 30988224
[TBL] [Abstract][Full Text] [Related]
25. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
26. The role of TSC1 and TSC2 proteins in neuronal axons.
Karalis V; Wood D; Teaney NA; Sahin M
Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
[TBL] [Abstract][Full Text] [Related]
27. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.
Hodges AK; Li S; Maynard J; Parry L; Braverman R; Cheadle JP; DeClue JE; Sampson JR
Hum Mol Genet; 2001 Dec; 10(25):2899-905. PubMed ID: 11741833
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin.
Nellist M; van Slegtenhorst MA; Goedbloed M; van den Ouweland AM; Halley DJ; van der Sluijs P
J Biol Chem; 1999 Dec; 274(50):35647-52. PubMed ID: 10585443
[TBL] [Abstract][Full Text] [Related]
29. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.
Aicher LD; Campbell JS; Yeung RS
J Biol Chem; 2001 Jun; 276(24):21017-21. PubMed ID: 11290735
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
31. Renal Transcriptome and Metabolome in Mice with Principal Cell-Specific Ablation of the Tsc1 Gene: Derangements in Pathways Associated with Cell Metabolism, Growth and Acid Secretion.
Zahedi K; Barone S; Brooks M; Murray Stewart T; Casero RA; Soleimani M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142537
[TBL] [Abstract][Full Text] [Related]
32. Tuberous Sclerosis Complex in Chinese patients: Phenotypic analysis and mutational screening of TSC1/TSC2 genes.
Lin S; Zeng JB; Zhao GX; Yang ZZ; Huang HP; Lin MT; Wu ZY; Wang N; Chen WJ; Fang L
Seizure; 2019 Oct; 71():322-327. PubMed ID: 31525612
[TBL] [Abstract][Full Text] [Related]
33. Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece.
Avgeris S; Fostira F; Vagena A; Ninios Y; Delimitsou A; Vodicka R; Vrtel R; Youroukos S; Stravopodis DJ; Vlassi M; Astrinidis A; Yannoukakos D; Voutsinas GE
Sci Rep; 2017 Dec; 7(1):16697. PubMed ID: 29196670
[TBL] [Abstract][Full Text] [Related]
34. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
35. Pam and its ortholog highwire interact with and may negatively regulate the TSC1.TSC2 complex.
Murthy V; Han S; Beauchamp RL; Smith N; Haddad LA; Ito N; Ramesh V
J Biol Chem; 2004 Jan; 279(2):1351-8. PubMed ID: 14559897
[TBL] [Abstract][Full Text] [Related]
36. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase.
Chong-Kopera H; Inoki K; Li Y; Zhu T; Garcia-Gonzalo FR; Rosa JL; Guan KL
J Biol Chem; 2006 Mar; 281(13):8313-6. PubMed ID: 16464865
[TBL] [Abstract][Full Text] [Related]
37. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
38. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
39. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
40. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis.
Jones AC; Daniells CE; Snell RG; Tachataki M; Idziaszczyk SA; Krawczak M; Sampson JR; Cheadle JP
Hum Mol Genet; 1997 Nov; 6(12):2155-61. PubMed ID: 9328481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
